Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$59.3 million.

  • Summit Therapeutics' Net Cash Flow fell 19096.73% to -$59.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.8 million, marking a year-over-year increase of 10697.13%. This contributed to the annual value of $33.8 million for FY2024, which is 10584.41% up from last year.
  • Per Summit Therapeutics' latest filing, its Net Cash Flow stood at -$59.3 million for Q3 2025, which was down 19096.73% from $86.3 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Net Cash Flow registered a high of $525.3 million during Q4 2022, and its lowest value of -$578.1 million during Q1 2023.
  • In the last 5 years, Summit Therapeutics' Net Cash Flow had a median value of $757000.0 in 2021 and averaged $9.1 million.
  • Per our database at Business Quant, Summit Therapeutics' Net Cash Flow skyrocketed by 663472.26% in 2022 and then tumbled by 1002415.45% in 2023.
  • Over the past 5 years, Summit Therapeutics' Net Cash Flow (Quarter) stood at -$8.0 million in 2021, then surged by 6634.72% to $525.3 million in 2022, then tumbled by 90.98% to $47.4 million in 2023, then crashed by 76.36% to $11.2 million in 2024, then tumbled by 629.95% to -$59.3 million in 2025.
  • Its last three reported values are -$59.3 million in Q3 2025, $86.3 million for Q2 2025, and $106.6 million during Q1 2025.